ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Janssens, H.
Right arrow Articles by Tiddens, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Janssens, H.
Right arrow Articles by Tiddens, H.
Eur Respir J 1999; 13: 787-791
Copyright © ERS Journals Ltd 1999

Clinical Trial

Variability of aerosol delivery via spacer devices in young asthmatic children in daily life

HM Janssens, SG Devadason, WC Hop, PN LeSouef, JC De Jongste, and HA Tiddens

Pressurized metered dose inhalers (pMDI) are widely used together with spacers for the treatment of asthma in children. However, the variability of daily medication dose for pMDI/spacer combinations is not known. Electrostatic charge is a potential source of dose variability. Metal spacers have no static charge. This study assessed and compared within-subject variability of aerosol delivery of metal and plastic spacers. This was a randomized, crossover study in children with stable asthma aged 1-4 (group I, n=17) and 5-8 (group II, n=16) yrs. In both groups the amount of drug delivered to the mouth by a metal spacer (Nebuchamber) and one of two plastic (polycarbonate) spacers, i.e. Babyhaler in group I and Volumatic in group II was measured. The metal and plastic spacers were tested at home in a randomized order for 7 days each, using budesonide (200 microg b.i.d.). Aerosol was collected on a filter positioned between spacer and facemask or mouth. Budesonide on the filter was assessed by high performance liquid chromatography. The mean filter dose for each child (mean+/-SD) during the 7 days was expressed as a percentage of the nominal dose. Within-subject variability was expressed as coefficient of variation (CV). Mean filter dose in group I was 41.7+/-10.1% for Nebuchamber and 26.0+/-4.0% for Babyhaler (p<0.001). Mean filter dose in group II was 50.2+/-9.2% for Nebuchamber and 19.4+/-7.2% for Volumatic (p<0.001). Mean CV in group I was 34% for Nebuchamber and 37% for Babyhaler (p=0.44). Mean CV in group II was 23% for Nebuchamber and 34% for Volumatic (p=0.003). There was substantial within-subject dose variability in aerosol delivery in children using a pMDI/spacer at home. This variability was lower for the metal than for the plastic spacer in children 5-8 yrs of age. The dose delivered to the mouth was about two-fold higher for the metal than the plastic spacer independent of age.


This article has been cited by other articles:


Home page
 Eur Respir JHome page
P. L. P. Brand, E. Baraldi, H. Bisgaard, A. L. Boner, J. A. Castro-Rodriguez, A. Custovic, J. de Blic, J. C. de Jongste, E. Eber, M. L. Everard, et al.
Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach
Eur. Respir. J., October 1, 2008; 32(4): 1096 - 1110.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
J. Esposito-Festen, H. Ijsselstijn, W. Hop, F. van Vliet, J. de Jongste, and H. Tiddens
Aerosol Therapy by Pressured Metered-Dose Inhaler-Spacer in Sleeping Young Children: To Do or Not to Do?
Chest, August 1, 2006; 130(2): 487 - 492.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
Inhalation devices
Can. Med. Assoc. J., September 13, 2005; 173(6_suppl): S39 - S45.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
G.W. 't Jong, I.A. Eland, M.C.J.M. Sturkenboom, J.N. van den Anker, and B.H.C. Stricker
Unlicensed and off-label prescription of respiratory drugs to children
Eur. Respir. J., February 1, 2004; 23(2): 310 - 313.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
J T Hayden, N Smith, D A Woolf, P W Barry, and C O'Callaghan
A randomised crossover trial of facemask efficacy
Arch. Dis. Child., January 1, 2004; 89(1): 72 - 73.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
I Amirav, I Balanov, M Gorenberg, D Groshar, and A S Luder
Nebuliser hood compared to mask in wheezy infants: aerosol therapy without tears!
Arch. Dis. Child., August 1, 2003; 88(8): 719 - 723.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
P M Watt, B Clements, S G Devadason, and G M Chaney
Funhaler spacer: improving adherence without compromising delivery
Arch. Dis. Child., July 1, 2003; 88(7): 579 - 581.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
B. Knorr, L. M. Franchi, H. Bisgaard, J. H. Vermeulen, P. LeSouef, N. Santanello, T. M. Michele, T. F. Reiss, H. H. Nguyen, and D. L. Bratton
Montelukast, a Leukotriene Receptor Antagonist, for the Treatment of Persistent Asthma in Children Aged 2 to 5 Years
Pediatrics, September 1, 2001; 108(3): e48 - 48.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
I. Amirav and M. T. Newhouse
Aerosol Therapy With Valved Holding Chambers in Young Children: Importance of the Facemask Seal
Pediatrics, August 1, 2001; 108(2): 389 - 394.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
M. L EVERARD
CFC transition: the Emperor's new clothes. Each class of drug deserves a delivery system that meets its own requirements
Thorax, October 1, 2000; 55(10): 811 - 814.
[Full Text]

Home page
 Arch. Dis. Child.Home page
M. L EVERARD
Trying to deliver aerosols to upset children is a thankless task
Arch. Dis. Child., May 1, 2000; 82(5): 428a - 428.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the European Respiratory Society.